In early October, the FDA announced that the two-year shortages of Mounjaro and Zepbound were resolved. After pushback from compounding pharmacies, the agency reaffirmed the decision on Dec. 19.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
